ClinicalTrials.gg
Enrolling by invitationNCT04682145Updated Oct 8, 2026

Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol

An observational study in Haemophilia A, sponsored by Novo Nordisk A/S. Enrolling by invitation at 1 site in Denmark. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Novo Nordisk A/S · Observational

How we know

Updated Oct 8, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
50
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 92 studies in Hemophilia A by Novo Nordisk A/S — 8 open to participants now, 12 under way, 5 of them phase 3. Hemophilia A · Novo Nordisk A/S.

Planned enrollment
22nd of 32
50 · median 86
Started
2020
with 2 others
Observational
32 of 92
6 open now
Primary completion
2026-12
later than 4 of 11 live
Registered
73rd of 92
by date

Among the 92 studies in Hemophilia A by Novo Nordisk A/S, this one is the 22nd largest by planned enrollment of the 32 observational ones that give a count, is one of 3 that started in 2020, is one of 32 observational ones, reaches primary completion later than 4 of the 11 other live ones, and was the 73rd registered.

Hemophilia A

845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

8 of the 92 studies in Hemophilia A by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Hemophilia A by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This non-interventional study concerns a safety data collection based on adverse event data from a third-party registry (European Haemophilia Safety Surveillance System, EUHASS) that includes information about adverse events from patients with haemophilia A treated with turoctocog alfa pegol. There is no extra burden to the patients by participating in this registry-based data collection.

03

Conditions studied

  • Haemophilia A

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients with haemophilia A treated with turoctocog alfa pegol and reporting adverse events to EUHASS.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participation in the European Haemophilia Safety Surveillance System (EUHASS).

Exclusion criteria

Exclusion Criteria:

  • N/A
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Haemophilia A patients

    All patients with haemophilia A treated with turoctocog alfa pegol and reporting adverse events to EUHASS.

    Drug: Turoctocog alfa pegol

Interventions

  • Patients will be treated with commercially available turoctocog alfa pegol according to routine clinical practice at the discretion of the treating physician. A decision to initiate treatment with commercially available turoctocog alfa pegol has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in the registry in scope.

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs) reported to the registry with suspected relation to turoctocog alfa pegol, Adverse Drug Reactions (ADRs), in patients with haemophilia A for renal, hepatic and neurological events.

    Count

    Time frame: From start to end of data collection (December 2019 to January 2025)

Secondary outcomes

  1. Other AEs reported to the registry during the study period with suspected relation to turoctocog alfa pegol in patients with haemophilia A

    Count. Includes ADRs of special interest (de novo FVIII inhibitors equal to or above 0.6 Bethesda Units (BU)); anaphylaxis and other allergic reactions; thromboembolic events).

    Time frame: From start to end of data collection (December 2019 to January 2025)

07

Study locations

1 site
  • Novo Nordisk Investigational Site
    Søborg, 2860, Denmark
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2020 (actual). Primary completion is estimated for Dec 2026, 71 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Feb 2026 → Dec 2026 and completion Feb 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2020
First posted
Dec 23, 2020
StartActual
Dec 9, 2020
Primary completionEst.
Dec 1, 2026was Feb 2026
CompletionEst.
Dec 1, 2026was Feb 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Feb 1, 2026→Dec 1, 2026
Oct 8, 2026
Study completion
Feb 1, 2026→Dec 1, 2026
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Primary completion Feb 1, 2026→Dec 1, 2026
    Study completion Feb 1, 2026→Dec 1, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04682145
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 23, 2020
Start date
Dec 9, 2020
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Oct 8, 2026

Study contacts

Clinical Reporting Anchor & Disclosure (2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion